Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: A pooled patient-level meta-analysis of randomized trials

被引:51
|
作者
De Luca, Giuseppe [1 ]
Smits, Peter [2 ]
Hofma, Sjoerd H. [3 ]
Di Lorenzo, Emilio [4 ]
Vlachojannis, Georgios J. [2 ]
van't Hof, Arnoud W. J. [5 ]
van Boven, Ad J. [3 ]
Kedhi, Elvin [5 ]
Stone, Gregg W. [6 ]
Suryapranata, Harry [7 ]
机构
[1] Eastern Piedmont Univ, Div Cardiol, Osped Maggiore della Carita, Novara, Italy
[2] Maasstad Hosp, Div Cardiol, Rotterdam, Netherlands
[3] Leeuwarden Med Ctr, Div Cardiol, Leeuwarden, Netherlands
[4] SG Moscati, Div Cardiol, Avellino, Italy
[5] ISALA, Div Cardiol, Zwolle, Netherlands
[6] Columbia Univ, Med Ctr, Cardiovasc Res Fdn, New York, NY USA
[7] Radboud Univ Nijmegen Med Ctr, Dept Cardiol, Nijmegen, Netherlands
关键词
ELEVATION MYOCARDIAL-INFARCTION; BARE-METAL STENTS; PERCUTANEOUS CORONARY INTERVENTION; PATIENTS RISK PROFILE; 5-YEAR FOLLOW-UP; BIODEGRADABLE POLYMER; CLINICAL-IMPLICATIONS; BALLOON ANGIOPLASTY; REGRESSION ANALYSIS; REVASCULARIZATION;
D O I
10.1016/j.ijcard.2017.06.022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Several concerns have emerged about the higher risk of very late stent thrombosis (ST) with first generation drug-eluting stent (DES) especially among STEMI patients. Newer generation DES has demonstrated to reduce ST at mid-term follow-up. Therefore, the aim of the present study is to performan individual patient's data meta-analysis of trials comparing 1st generation DES vs. 2nd generation DES (everolimus-eluting stent, EES) in patients undergoing primary percutaneous coronary intervention (PCI) for STEMI. Methods: We performed a formal search of electronic databases (MEDLINE and CENTRAL) and scientific session presentations from January 2010 to June 2016. We included all completed randomized trials comparing 1st vs. EES for patient presenting with STEMI. Results: Individual patients data were obtained from 3 trials, including a total of 1581 patients (686 or 43.4% randomized to 1st generation DES and 895 or 56.4% randomized to EES). At long-term follow-up (1584 +/- 588 days), EES did not significantly reduce mortality (7.8.% vs 11.7%, HR [95% CI]= 0.77 [0.52, 1.13], p= 0.18, p(heterogeneity) = 0.93), cardiac mortality (6.2% vs 7.6%, HR [95% CI] = 0.90 [0.56, 1.44], p = 0.65, p(heterogeneity) = 0.85), and reinfarction (8.1% versus 11.2%, respectively; HR [95% CI] = 0.74 [0.51, 1.07], p = 0.11, p(heterogeneity) = 0.52). However, EES significantly reduced the occurrence of ST (3.4% versus 6.1% respectively, HR [95% CI] = 0.56 [0.32, 0.97], p = 0.04, p(heterogeneity) = 0.42) and target vessel revascularization (TVR) (14.2% versus 20.1%; HR [95% CI]= 0.63 [0.42, 0.96], p = 0.03, p(heterogeneity) = 0.55). Landmark analysis showed more consistent benefits in ST with EES within 1 year, whereas benefits in TVR were mostly observed later than 1 year. Conclusions: The present pooled patient-levelmeta-analysis demonstrates that among STEMI patients undergoing primary PCI, EES as compared to 1st generationDES is associatedwith a significant reduction in ST and TVR at long-term follow-up. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:121 / 127
页数:7
相关论文
共 50 条
  • [1] Sirolimus-eluting versus paclitaxel-eluting stent in primary angioplasty: a pooled patient-level meta-analysis of randomized trials
    De Luca, Giuseppe
    Wirianta, Jeffrey
    Lee, Jae-Hwan
    Kaiser, Christoph
    Di Lorenzo, Emilio
    Suryapranata, Harry
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2014, 38 (03) : 355 - 363
  • [2] Drug-Eluting vs Bare-Metal Stents in Primary Angioplasty A Pooled Patient-Level Meta-analysis of Randomized Trials
    De Luca, Giuseppe
    Dirksen, Maurits T.
    Spaulding, Christian
    Kelbaek, Henning
    Schalij, Martin
    Thuesen, Leif
    van der Hoeven, Bas
    Vink, Marteen A.
    Kaiser, Christoph
    Musto, Carmine
    Chechi, Tania
    Spaziani, Gaia
    Diaz de la Llera, Luis Salvador
    Pasceri, Vincenzo
    Di Lorenzo, Emilio
    Violini, Roberto
    Cortese, Giuliana
    Suryapranata, Harry
    Stone, Gregg W.
    ARCHIVES OF INTERNAL MEDICINE, 2012, 172 (08) : 611 - 621
  • [3] Drug-Eluting Balloons Versus Everolimus-Eluting Stents for In-Stent Restenosis: A Meta-Analysis of Randomized Trials
    Elgendy, Islam Y.
    Mahmoud, Ahmed N.
    Elgendy, Akram Y.
    Mojadidi, Mohammad K.
    Elbadawi, Ayman
    Eshtehardi, Parham
    Jose Perez-Vizcayno, Maria
    Wayangankar, Siddharth A.
    Jneid, Hani
    Anderson, R. David
    Alfonso, Fernando
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2019, 20 (07) : 612 - 618
  • [4] Comparison of Drug-Coated Balloon Angioplasty vs. Drug-Eluting Stent Implantation for Drug-Eluting Stent Restenosis in the Routine Clinical Practice: A Meta-Analysis of Randomized Controlled Trials
    Zhu, Yong
    Liu, Kesen
    Kong, Xiangyun
    Nan, Jing
    Gao, Ang
    Liu, Yan
    Han, Hongya
    Li, Hong
    Zhu, Huagang
    Zhang, Jianwei
    Zhao, Yingxin
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [5] Impact of the Everolimus-Eluting Stent on Stent Thrombosis A Meta-Analysis of 13 Randomized Trials
    Baber, Usman
    Mehran, Roxana
    Sharma, Samin K.
    Brar, Somjot
    Yu, Jennifer
    Suh, Jung-Won
    Kim, Hyo-Soo
    Park, Seung-Jung
    Kastrati, Adnan
    de Waha, Antoinette
    Krishnan, Prakash
    Moreno, Pedro
    Sweeny, Joseph
    Kim, Michael C.
    Suleman, Javed
    Pyo, Robert
    Wiley, Jose
    Kovacic, Jason
    Kini, Annapoorna S.
    Dangas, George D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (15) : 1569 - 1577
  • [6] Paclitaxel-eluting versus bare metal stents in primary PCI: a pooled patient-level meta-analysis of randomized trials
    De Luca, Giuseppe
    Dirksen, Maurits T.
    Kelbaek, Henning
    Thuesen, Leif
    Vink, Marteen A.
    Kaiser, Christoph
    Chechi, Tania
    Spaziani, Gaia
    Di Lorenzo, Emilio
    Suryapranata, Harry
    Stone, Gregg W.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 39 (01) : 101 - 112
  • [7] Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era Pooled Analysis of the Korean Multicenter Drug-Eluting Stent Registry
    Lee, Joo Myung
    Kang, Jeehoon
    Lee, Euijae
    Hwang, Doyeon
    Rhee, Tae-Min
    Park, Jonghanne
    Kim, Hack-Lyoung
    Lee, Sang Eun
    Han, Jung-Kyu
    Yang, Han-Mo
    Park, Kyung Woo
    Na, Sang-Hoon
    Kang, Hyun-Jae
    Koo, Bon-Kwon
    Kim, Hyo-Soo
    JACC-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (20) : 2097 - 2109
  • [8] Comparison Among Drug-Eluting Balloon, Drug-Eluting Stent, and Plain Balloon Angioplasty for the Treatment of In-Stent Restenosis A Network Meta-Analysis of 11 Randomized, Controlled Trials
    Lee, Joo Myung
    Park, Jonghanne
    Kang, Jeehoon
    Jeon, Ki-Hyun
    Jung, Ji-hyun
    Lee, Sang Eun
    Han, Jung-Kyu
    Kim, Hack-Lyoung
    Yang, Han-Mo
    Park, Kyung Woo
    Kang, Hyun-Jae
    Koo, Bon-Kwon
    Kim, Hyo-Soo
    JACC-CARDIOVASCULAR INTERVENTIONS, 2015, 8 (03) : 382 - 394
  • [9] Comparison of drug-eluting balloon versus drug-eluting stent treatment of drug-eluting stent in-stent restenosis: A meta-analysis of available evidence
    Bajraktari, Gani
    Jashari, Haki
    Ibrahimi, Pranvera
    Alfonso, Fernando
    Jashari, Fisnik
    Ndrepepa, Gjin
    Elezi, Shpend
    Henein, Michael Y.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 218 : 126 - 135
  • [10] Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials
    Alfonso, Fernando
    Perez-Vizcayno, Maria Jose
    del Blanco, Bruno Garcia
    Garcia-Touchard, Arturo
    Lopez-Minguez, Jose-Ramon
    Masotti, Monica
    Zueco, Javier
    Melgares, Rafael
    Mainar, Vicente
    Moreno, Raul
    Dominguez, Antonio
    Sanchis, Juan
    Bethencourt, Armando
    Moreu, Jose
    Cequier, Angel
    Marti, Vicens
    Otaegui, Imanol
    Bastante, Teresa
    Gonzalo, Nieves
    Jimenez-Quevedo, Pilar
    Cardenas, Alberto
    Fernandez, Cristina
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (07)